Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of autoimmune disease drug safety review as Amgen’s Tavneos scrutiny puts ANCA vasculitis treatment, FDA approval standards, liver risk, and rare disease evidence under sharper focus.
Pharma & Biotech

Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk

Find out how Amgen’s Tavneos data review could shape FDA withdrawal risk, liver safety scrutiny, and ANCA vasculitis care.

Read More
Representative image: An ophthalmic surgeon performs cataract surgery, reflecting ZEISS Medical Technology’s AT LUCIA toric 721P lens and the growing focus on precision intraocular lenses for astigmatism correction.
Medical Devices & Diagnostics

Could ZEISS’s new toric intraocular lens improve predictability in astigmatism correction?

Find out how ZEISS’s AT LUCIA toric 721P lens could improve cataract surgery precision and astigmatism correction.

Read More
Representative image of neuroimmunology research as Sanofi’s riliprubart Phase 3 trial halt puts CIDP treatment, complement inhibition, and rare neurology drug development under sharper focus.
Pharma & Biotech

Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus

Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.

Read More
Representative image: An ENT specialist explains a sinus procedure as Airiver Medical’s ESSpand Sinus Drug Coated Balloon trial highlights new drug-device approaches for chronic rhinosinusitis care.
Medical Devices & Diagnostics

Could Airiver Medical’s ESSpand balloon reduce repeat procedures in chronic rhinosinusitis?

Find out how Airiver Medical’s ESSpand pivotal trial could reshape chronic rhinosinusitis care and sinus surgery outcomes.

Read More
Representative image of oncology drug discovery as Parabilis Medicines’ IPO surge puts Helicon peptides, zolucatetide, desmoid tumors, and Wnt-driven cancer treatment under sharper focus.
Pharma & Biotech

Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution

Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.

Read More
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment

Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.

Read More
Representative image of cardiovascular drug research as Kardigan’s planned Nasdaq IPO puts precision heart medicines, late-stage clinical trials, and biotech investor appetite under sharper focus.
Pharma & Biotech

Kardigan’s $1.4bn IPO plan tests investor appetite for late-stage cardiovascular biotech

Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.

Read More
Representative image: A clinician reviews blood disorder data in a hospital setting, reflecting Johnson & Johnson’s IMAAVY Phase 2/3 results and the growing focus on FcRn-targeted treatment for warm autoimmune hemolytic anemia.
Pharma & Biotech

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.

Read More
Representative image of leukemia drug research as Enliven Therapeutics’ ELVN-001 data put chronic myeloid leukemia treatment, Phase 3 trial planning, and targeted oncology therapy under sharper focus.
Pharma & Biotech

Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies

Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.

Read More
Representative image: A dermatologist examines an eczema flare, reflecting how EBGLYSS and other atopic dermatitis biologics are shifting the treatment conversation toward fewer injections, longer disease control, and lower patient burden.
Features & Analysis

How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy

Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.

Read More